phrykt

Anavex Life Sciences Corp. (AVXL): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of AVXL were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Anavex Life Sciences

From the latest filings

Overall: about as much buying as selling. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns AVXL

176 funds and institutions reported AVXL shares worth $97.8M at the end of Q2 2026, about 42% of the company. The largest holder is BlackRock, Inc. with 9.0%.

Funds and institutions (13F) 42%Everyone else 58%

10 largest owners, by share of the company

BlackRock, Inc.9.0%
Vanguard Capital Management LLC4.5%
Two Sigma Investments, LP3.4%
Geode Capital Management, LLC2.7%
State Street Corp2.2%
Federated Hermes, Inc.1.2%
AQR Capital Management LLC1.1%
Vanguard Portfolio Management LLC1.1%
Summit Financial, LLC1.0%
Goldman Sachs Group Inc1.0%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.8.06M9.02%$20.9M+6%
Vanguard Capital Management LLC4.05M4.54%$10.5M+5%
Two Sigma Investments, LP3.05M3.41%$7.9M-6%
Geode Capital Management, LLC2.41M2.69%$6.2M+10%
State Street Corp1.92M2.15%$5M-57%
Federated Hermes, Inc.1.07M1.20%$2.8M+101%
AQR Capital Management LLC963,0141.08%$2.5M+27%
Vanguard Portfolio Management LLC948,6331.06%$2.5M+21%
Summit Financial, LLC909,4301.02%$2.4M-3%
Goldman Sachs Group Inc890,6341.00%$2.3M+11%
Marshall Wace, LLP889,5231.00%$2.3M+112%
Northern Trust Corp784,4940.88%$2M+8%
Barclays PLC754,2260.84%$2M+40%
Charles Schwab Investment Management Inc734,7950.82%$1.9M-3%
Sixth Street Partners Management Company, L.P.734,7950.82%$1.9M–
Bank of America Corp654,2950.73%$1.7M-24%
Vanguard Fiduciary Trust Co621,4510.70%$1.6M-4%
UBS Group AG620,3740.69%$1.6M+9%
Private Advisor Group, LLC504,0000.56%$1.3M+1%
LPL Financial LLC406,1090.45%$1.1M-3%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No AVXL insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AVXL short interest

High short interest. 12.9% of AVXL shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went down 38%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 11.92M AVXL shares were sold short, 12.9% of the shares outstanding, down 5.0% from the report before. At the average daily volume of 1.18M shares, buying them all back would take about 10.1 trading days (days to cover).

Shares short, % of all shares

12.9%May 15Oct 3022.8%

Days to cover

10.1May 15Oct 3027.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202611.92M12.86%-5%1.18M10.1
Oct 15, 202612.55M13.54%-8%1.55M8.1
Sep 30, 202613.57M14.64%-5%1.00M13.6
Sep 15, 202614.33M15.46%+3%570,26025.1
Aug 31, 202613.90M14.99%-1%834,18416.7
Aug 14, 202614.11M–-2%985,60114.3
Jul 31, 202614.43M–+2%999,85514.4
Jul 15, 202614.14M–-1%906,50815.6
Jun 30, 202614.23M–-19%2.07M6.9
Jun 15, 202617.53M–-7%1.15M15.2
May 29, 202618.83M21.08%-2%1.13M16.6
May 15, 202619.23M21.53%+1%980,25119.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Anavex Life Sciences company events

Anavex Life Sciences filed 21 reports on Form 8-K in the last 12 months, 7 of them about an important change (leadership, control, listing). The latest was on Nov 3, 2026.

  1. Nov 3, 2026LeadershipThe Board of Directors of Anavex Life Sciences Corp., appointed Terrie Kellmeyer, Ph.D. as the Company’s Chief Executive Officer and President effective immediately. Filing
  2. Nov 2, 2026LeadershipEach of Dr. Jiong Ma, Mr. Gautam Patel and Dr. Adrian Senderowicz resigned from the Board of Directors of Anavex Life Sciences Corp. effective as of October 28, 2026. Filing
  3. Oct 20, 2026AnnouncementAnavex Life Sciences Corp. issued a press release providing an update on the clinical development of blarcamesine (ANAVEX ® 2-73), including the completion of the clinical conduct of two pharmacology studies: (i) an ADME (absorption, distribution, metabolism and excretion) study and (ii) a DDI… Filing
  4. Oct 15, 2026AnnouncementAnavex Life Sciences Corp. issued a press release announcing that it received notification from the U.S. Food and Drug Administration that the Company may proceed with its planned clinical study under its investigational new drug application for blarcamesine in Fragile X syndrome. Filing
  5. Sep 28, 2026ControlAs further described under Item 5.07 of this Current Report on Form 8-K, Anavex Life Sciences Corp. held its 2026 Annual Meeting of Stockholders on September 24, 2026. Filing
  6. Sep 9, 2026AnnouncementAs previously disclosed, Anavex Life Sciences Corp. is prioritizing the advancement of its ANAVEX®2-73 (blarcamesine) clinical development pipeline in early Alzheimer’s disease, Rett syndrome and Fragile X syndrome in the United States, and the Company is moving forward with the initiation of a… Filing
  7. Sep 2, 2026AnnouncementAs previously disclosed, on May 20, 2026, Anavex Life Sciences Corp. received a delinquency notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, as a result of the Company’s inability to timely file its Quarterly Report on Form 10-Q for the… Filing
  8. Aug 25, 2026ResultsReleased financial results. Filing
  9. Aug 17, 2026AnnouncementShared information with investors. Filing
  10. Aug 11, 2026AnnouncementShared information with investors. Filing
  11. Aug 3, 2026AnnouncementShared information with investors. Filing
  12. Jul 30, 2026ResultsReleased financial results. Filing
  13. Jul 20, 2026AnnouncementAnavex Life Sciences Corp. timely submitted its plan to the Listing Qualifications Department of The Nasdaq Stock Market LLC to regain compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and… Filing
  14. Jun 26, 2026AnnouncementThe Board of Directors of Anavex Life Sciences Corp. established September 24, 2026, as the date of the Company’s 2026 Annual Meeting of Stockholders and July 31, 2026, as the record date for the determination of stockholders entitled to notice of and to vote at the 2026 Annual Meeting. Filing
  15. May 22, 2026ListingAnavex Life Sciences Corp. received a delinquency notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, as a result of the Company’s inability to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, the… Filing
  16. May 15, 2026LeadershipFelix Lauscher, who had held the title of Chief Operating Officer of Anavex Life Sciences Corp. since March 1, 2026, departed from the Company as part of a broader reorganization of duties at the Company following the appointment of Dr. Terrie Kellmeyer as the Company’s Interim Chief Executive… Filing
  17. May 6, 2026LeadershipA special committee composed of independent directors of the Board of Directors of Anavex Life Sciences Corp. terminated the employment of Christopher Missling, PhD as the Company’s Chief Executive Officer for Cause (as defined in the Employment Agreement, dated as of June 27, 2013, between Dr.… Filing
  18. Mar 25, 2026AnnouncementAnavex Life Sciences Corp. issued a press release announcing that it has withdrawn its application for the marketing authorization of blarcamesine in the EU as an add-on therapy for the treatment of early Alzheimer’s disease in adults, which had been under review by the European Medicines Agency… Filing
  19. Feb 25, 2026LeadershipThe Board of Directors of Anavex Life Sciences Corp., a Nevada corporation, upon the recommendation of its Nominating and Corporate Governance Committee, appointed Axel Paeger, MD, MBA, MBI as a member of the Board, effective February 23, 2026, to fill a vacancy on the Board. Filing
  20. Feb 9, 2026ResultsReleased financial results. Filing
  21. Nov 25, 2025ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Anavex Life Sciences financials

Famous investors that hold AVXL

3 of the 50 well-known investors we track reported holding AVXL in their latest 13F filing. The largest position is Ken Griffin's, worth $1.1M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026548,819$1.1M0.0%+67%
Jim Simons · Renaissance TechnologiesQ3 202679,999$162K0.0%New
Steve Cohen · Point72 Asset ManagementQ3 202677,502$157K0.0%-51%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Anavex Life Sciences Corp. (AVXL) stock

Who owns the most AVXL stock?

The largest reported owner of Anavex Life Sciences Corp. (AVXL) is BlackRock, Inc., with 9.0% of the company. In total, 176 funds and institutions reported holding AVXL at the end of Q2 2026, together about 42% of the shares. See the largest owners.

Are AVXL insiders buying or selling?

No AVXL insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in AVXL?

As of Oct 30, 2026, 11.92M AVXL shares were sold short, 12.9% of the shares outstanding, down 5.0% from the report before. At the average daily volume of 1.18M shares, buying them all back would take about 10.1 trading days (days to cover). See the history.

Which famous investors hold AVXL?

3 of the 50 well-known investors we track reported AVXL in their latest 13F filing, including Ken Griffin, Jim Simons, Steve Cohen. The largest position is worth $1.1M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.